IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
Mrozek, E.1,2; Kolesar, J.3; Young, D.4; Allen, J.2,5; Villalona-Calero, M.1; Shapiro, C. L.1,2
关键词breast cancer irinotecan mitomycin topoisomerase I
刊名ANNALS OF ONCOLOGY
2008-08-01
DOI10.1093/annonc/mdn154
19期:8页:1417-1422
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]COLON-CARCINOMA CELLS ; NQO1 GENE-EXPRESSION ; DT-DIAPHORASE ; PLUS VINBLASTINE ; ANTHRACYCLINE ; TAXANE ; CAPECITABINE ; DOCETAXEL ; VINORELBINE ; COMBINATION
英文摘要

Background: Preclinical studies show that mitomycin-C (MMC) followed by irinotecan (CPT-11) is synergistic. Therefore, we evaluated the toxicity and efficacy of sequentially administered low-dose MMC and CPT-11 in patients (pts) with pretreated metastatic breast cancer (MBC). Secondary objective was to evaluate the correlation between MMC-induced topoisomerase I (TOPO I) expression and NAD(P)H:quinone oxireductase 1 (NQO1) genotypes in peripheral blood mononuclear cells (PBMC) and efficacy or toxicity of the regimen.

Design: Thirty-two pts received MMC i.v. 6 mg/m(2) day 1 and CPT-11 i.v. 125 mg/m(2) days 2 and 8 every 28 days for maximum of six cycles. TOPO I expression and NQO1 reductase genotyping in 23 of 32 (72%) pts were assayed by PCR.

Results: The median time to progression (TTP) was 4.7 months (95% confidence interval 4.0-5.4 months). TOPO I expression was increased 5- to 10-fold and 20- to 30-fold in PBMC at 24 and 168 h, respectively. There was no relationship between these markers and efficacy or toxicity of the regimen.

Conclusions: Sequential low-dose MMC and CPT-11 was active and tolerable by pretreated MBC pts. Future trials should focus on less pretreated MBC pts and sequential tumor biopsies to test the hypothesis that increased intratumoral expression of TOPO I is related to efficacy.

语种英语
WOS记录号WOS:000258136800009
引用统计
被引频次:15[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63587
专题北京大学临床肿瘤学院
作者单位1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
2.Ohio State Univ, Med Ctr, Arthur G James Canc Hosp, Comprehens Breast Hlth Serv, Columbus, OH 43210 USA
3.Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
4.Ohio State Univ, Ctr Comprehens Canc, Ctr Biostat, Columbus, OH 43210 USA
5.Ohio State Univ, Med Ctr, Ctr Comprehens Canc, Clin Trials Off, Columbus, OH 43210 USA
推荐引用方式
GB/T 7714
Mrozek, E.,Kolesar, J.,Young, D.,et al. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)[J]. ANNALS OF ONCOLOGY,2008,19(8):1417-1422.
APA Mrozek, E.,Kolesar, J.,Young, D.,Allen, J.,Villalona-Calero, M.,&Shapiro, C. L..(2008).Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).ANNALS OF ONCOLOGY,19(8),1417-1422.
MLA Mrozek, E.,et al."Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)".ANNALS OF ONCOLOGY 19.8(2008):1417-1422.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mrozek, E.]的文章
[Kolesar, J.]的文章
[Young, D.]的文章
百度学术
百度学术中相似的文章
[Mrozek, E.]的文章
[Kolesar, J.]的文章
[Young, D.]的文章
必应学术
必应学术中相似的文章
[Mrozek, E.]的文章
[Kolesar, J.]的文章
[Young, D.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。